Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis

References

• Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–617.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Sakata T, Palumbo J,MA. A 24-week, phase III, double-blind, parallel-group study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS). Neurology. 2015;86:S189.
   Google Scholar
• Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7:241–245.
   PubMed Web of Science ®Google Scholar
• Kruman II, Pedersen WA, Springer JE, et al. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol. 1999;160(1):28–39.
   PubMed Web of Science ®Google Scholar
• Cookson MR, Menzies FM, Manning P, et al. Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:75–85.
   PubMed Web of Science ®Google Scholar
• Beckman JS, Estevez AG, Crow JP, et al. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci. 2001;24(11 Suppl):S15–20.
   Google Scholar
• Andersen PM. Genetics of sporadic ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(Suppl 1):S37–41.
   PubMedGoogle Scholar
• Wegorzewska I, Baloh RH. TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis. 2011;8:262–274.
   PubMed Web of Science ®Google Scholar
• Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48:629–641.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, et al. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999;46:129–131.
   PubMed Web of Science ®Google Scholar
• Shimohama S, Akaike A, Kimura J. Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation. Ann NY Acad Sci. 1996;777:356–361.
   PubMed Web of Science ®Google Scholar
• Sawada H, Shimohama S, Tamura Y, et al. Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. J Neurosci Res. 1996;43:55–62.
   PubMed Web of Science ®Google Scholar
• Sawada H, Shimohama S. MPP(+) and glutamate in the degeneration of nigral dopaminergic neurons. Parkinsonism Relat Disord. 1999;5:209–215.
   PubMed Web of Science ®Google Scholar
• Urushitani M, Shimohama S, Kihara T, et al. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection. Ann Neurol. 1998;44:796–807.
   PubMed Web of Science ®Google Scholar
• Urushitani M, Nakamizo T, Inoue R, et al. N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+) overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx. J Neurosci Res. 2001;63:377–387.
   PubMed Web of Science ®Google Scholar
• Wagey R, Krieger C, Shaw CA. Abnormal dephosphorylation effect on NMDA receptor regulation in ALS spinal cord. Neurobiol Dis. 1997;4:350–355.
   PubMed Web of Science ®Google Scholar
• Abe K, Pan LH, Watanabe M, et al. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol Res. 1997;19:124–128.
   PubMed Web of Science ®Google Scholar
• Tabrizchi R. Edaravone Mitsubishi-Tokyo. Curr Opin Investig Drugs. 2000;1:347–354.
   PubMedGoogle Scholar
• Fujisawa A, Yamamoto Y. Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 2016;21:98–103.
   PubMed Web of Science ®Google Scholar
• Nagase M, Yamamoto Y, Miyazaki Y, et al. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21:104–112.
   PubMed Web of Science ®Google Scholar
• Zhang GL, Zhang WG, Du Y, et al. Edaravone ameliorates oxidative damage associated with Abeta25-35 treatment in PC12 cells. J Mol Neurosci. 2013;50:494–503.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Ishihara K, Ago Y, et al. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J Pharmacol Exp Ther. 2007;322:274–281.
   PubMed Web of Science ®Google Scholar
• Ito H, Wate R, Zhang J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213:448–455.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Iwasaki Y. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse. PLoS One. 2015;10:e0140316.
   PubMed Web of Science ®Google Scholar
• Aoki M, Warita H, Mizuno H, et al. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res. 2011;1382:321–325.
   PubMed Web of Science ®Google Scholar
• Takamatsu Y, Yamamoto M, Hisanaga N. Studies on the metabolic fate of MCI-186 in rats. Jpn Pharmacol Ther. 1996;24:176–181.
   Google Scholar
• Shibata H, Arai S, Isawa M, et al. Phase I trial of MCI-186 (edaravone). Jpn J Clin Pharmacol. 1998;29:864–876.
   Google Scholar